60 Degrees Pharmaceuticals receives Nasdaq delisting notice
Nasdaq has told 60 Degrees Pharmaceuticals it faces delisting after its shares traded below $1 for 30 straight business days. The company has requested a hearing.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
According to TradingView, citing filings with the SEC, Nasdaq informed the company on November 19, 2026 that its share price had stayed under $1.00 for 30 consecutive business days. That breaches Nasdaq Listing Rule 5550(a)(2), and the exchange has decided to delist the securities.
The company does not qualify for a standard compliance period because it carried out reverse stock splits within the previous year. It asked for a hearing by November 27, 2026. Until the Panel rules, the suspension and the Form 25-NSE filing are on hold.
why it matters
For markets, this is a sign of financial pressure at a small drug developer. The news concerns a single stock and is unlikely to move the broader market, but the Panel's decision will determine whether the shares stay listed on Nasdaq.
tags
instruments
sources
- 60 Degrees Pharmaceuticals Received Notice of Delisting — TradingView, 20 November 2026 at 22:03 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗